Inactive Instrument
Allied Corp. Stock Other OTC
Stocks
ALID
US0191141078
Pharmaceuticals
OTC Markets Traded| Market Cap | 1.3M 1.13M 1.06M 970K 1.83M 124M 1.85M 12.44M 4.86M 61.99M 4.9M 4.79M 205M | P/E 2023 |
-2.13x | P/E 2024 | -2.52x |
|---|---|---|---|---|---|
| Enterprise Value | 7.55M 6.56M 6.11M 5.62M 10.62M 718M 10.74M 72.07M 28.17M 359M 28.36M 27.74M 1.19B | EV / Sales 2023 |
394,366,816x | EV / Sales 2024 | 171,944,593x |
| Free-Float |
100% | Yield 2023 * |
-
| Yield 2024 | - |
| 1 day | -5.00% |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | - | |
Radka Milanova
CTO | Chief Tech/Sci/R&D Officer | 71 | - |
James Smeeding
PRN | Corporate Officer/Principal | - | 02/05/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
James Smeeding
BRD | Director/Board Member | - | 02/05/2020 |
Abdul Nnyenje
BRD | Director/Board Member | - | 21/10/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -5.00% | -5.00% | - | - | 117 | ||
| +1.85% | +4.08% | +61.11% | -10.53% | 2.34B | ||
| +2.85% | +6.96% | +69.71% | +118.92% | 1.65B | ||
| +4.17% | +2.00% | -44.11% | +161.90% | 463M | ||
| -.--% | +5.66% | +19.15% | +12.00% | 60.91M | ||
| Average | +0.82% | +0.25% | +26.47% | +70.57% | 1.13B | |
| Weighted average by Cap. | +2.48% | -1.31% | +52.90% | +54.85% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 0.07 0.06 0.06 0.05 0.1 6.86 0.1 0.69 0.27 3.43 0.27 0.26 11.36 | 0.1 0.08 0.08 0.07 0.14 9.15 0.14 0.92 0.36 4.57 0.36 0.35 15.15 |
| Net income | -10.68M -9.27M -8.64M -7.94M -15.02M -1.02B -15.18M -102M -39.83M -508M -40.09M -39.21M -1.68B | -3.98M -3.45M -3.22M -2.96M -5.59M -378M -5.65M -37.95M -14.84M -189M -14.93M -14.6M -626M |
| Net Debt | 5.65M 4.91M 4.58M 4.2M 7.95M 538M 8.04M 53.94M 21.09M 269M 21.22M 20.76M 890M | 6.25M 5.42M 5.06M 4.65M 8.79M 594M 8.88M 59.63M 23.31M 297M 23.46M 22.95M 984M |
Employees
-
Sector
Pharmaceuticals
















